MedTrace Logo

A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis

NCT01513070 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-08-05

No results posted yet for this study

Summary

This study investigates the effective power of angina pectoris after Quick-Acting Heart Reliever and isosorbide dinitrate interventing respectively the patients with moderate coronary stenosis for six months. At the same time, the studying will assess the plaque, myocardial blood-supplying,quality of life and observe the end point of the heart (including the myocardial revascularization, death and myocardial infarction). The purpose is to study the function of the blood-quickening stasis-transforming formula Quick-Acting Heart Reliever for moderate coronary stenosis lesions.

Conditions

Interventions

DRUG

Quick-Acting Heart Reliever

Quick-Acting Heart Reliever，200mg，tid，po. for six months

DRUG

Isosorbide Dinitrate

Isosorbide Dinitrate，10mg，tid，po. for six months

DRUG

Placebo of Isosorbide Dinitrate

Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months

DRUG

Aspirin Enteric-coated Tablets

Aspirin Enteric-coated Tablets，100mg，qd，po. for six months

DRUG

Placebo of Quick-Acting Heart Reliever

Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months

DRUG

Aspirin Enteric-coated Tablets

Aspirin Enteric-coated Tablets，100mg，qd，po. for six months

Sponsors & Collaborators

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Jie Wang, MD · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-07-31
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01513070 on ClinicalTrials.gov